{"filings":[{"id":1553479,"accession_number":"0001549595-26-000038","cik":1549595,"company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","form_type":"8-K","filed_at":"2026-07-09T20:09:51+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nurix enters $2.3B Roche collaboration for bexobrutideg; Q2 net loss $89.5M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Global collaboration with Roche for bexobrutideg: $700M upfront, up to $2.3B total; co-dev/co-commercialization in hematology, immunology, neurology.","Q2 FY2026 revenue $9.0M (down from $44.1M YoY); net loss $89.5M ($0.81/share) vs $43.5M loss prior year.","Cash, equivalents & marketable securities $443.5M as of May 31, 2026; pro-forma ~$1.14B including expected $700M Roche payment.","Bexobrutideg Phase 1a/1b CLL data: ORR 83% (Phase 1a) and 92.9% (Phase 1b Cohort 5); median PFS 22.1 months.","Enrollment continues in pivotal Phase 2 DAYBreak CLL-201; Phase 3 vs pirtobrutinib expected to start mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1802363286.5580997,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":981996,"accession_number":"0001549595-26-000034","cik":1549595,"company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","form_type":"8-K","filed_at":"2026-06-11T11:06:57+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Nurix reports Phase 1a/1b data for bexobrutideg: ORR 83% in R/R CLL, 92.9% in earlier-line","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1a ORR 83.0% (47 evaluable), median PFS 22.1 months; median 4 prior lines.","Phase 1b Cohort 5 (BTKi-treated, BCL2i-naïve): ORR 92.9% at 5.2 months follow-up; 18/19 on treatment.","Phase 1b Cohort 15 (BTKi-naïve, incl. treatment-naïve): ORR 84.2% at 4.9 months; 19/20 on treatment.","Safety: well-tolerated, no dose-limiting toxicities, no treatment-related Grade 5 events; AE discontinuation 5.6%.","Company plans Phase 3 monotherapy program and has Roche collaboration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1802363286.5580997,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":899716,"accession_number":"0001549595-26-000030","cik":1549595,"company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","form_type":"8-K","filed_at":"2026-06-08T10:11:32+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Nurix receives $700M upfront from Roche to co-develop BTK degrader bexobrutideg; potential $2.3B total","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront cash payment of $700 million; potential development, regulatory and sales milestones up to $2.3 billion total.","Development costs shared 40% Nurix / 60% Roche; U.S. profits and losses split equally.","Ex-U.S. royalties range from low-teens to high-teens on net sales; Roche leads commercialization outside U.S.","Expansion into immunology and neurology: Phase 2 trials planned in multiple sclerosis and chronic spontaneous urticaria.","Co-development and co-commercialization in U.S. across malignant hematology; Nurix becomes fully integrated biotech."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1802363286.5580997,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":470481,"accession_number":"0001549595-26-000028","cik":1549595,"company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","form_type":"8-K","filed_at":"2026-05-15T20:03:04+00:00","items":["5.07","9.01"],"status":"ready","headline":"Nurix Therapeutics 2026 annual meeting votes: directors elected, auditor ratified, say-on-pay approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected all three Class III director nominees: Arthur T. Sands (63.6M for, 16.3M withheld), Roger Dansey (79.6M for, 0.3M withheld), Paul M. Silva (59.3M for, 20.6M withheld).","Ratified PricewaterhouseCoopers LLP as independent auditor for FY2026 with 83.6M for, 0.2M against, 0.02M abstentions.","Approved non-binding advisory vote on named executive officer compensation: 72.5M for, 6.9M against, 0.6M abstentions, 3.8M broker non-votes.","Approximately 81% of voting power (83.7M shares) present, establishing a quorum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":1802363286.5580997,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93571,"accession_number":"0001549595-26-000024","cik":1549595,"company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","form_type":"8-K","filed_at":"2026-04-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nurix Q1 net loss $87.2M ($0.79); advancing bexobrutideg registrational program","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $6.3M vs $18.5M YoY; net loss $87.2M ($0.79) vs $56.4M ($0.67).","Cash $540.7M vs $592.9M at Nov 30, 2025; net burn ~$52M in quarter.","Enrolling Phase 2 DAYBreak CLL-201 for bexobrutideg; Phase 3 confirmatory trial planned mid-2026.","Healthy volunteer SAD/MAD study of new tablet formulation to support IND in immunology/inflammation.","Sanofi advancing STAT6 degrader NX-3911; Gilead advancing IRAK4 degrader GS-6791 in Phase 1."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":6252000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1802363286.5580997,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105306,"accession_number":"0001193125-26-096734","cik":1549595,"company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","form_type":"8-K","filed_at":"2026-03-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nurix Therapeutics ups ATM equity offering capacity to $413.65M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment No. 3 to Equity Distribution Agreement with Piper Sandler dated March 6, 2026.","Maximum aggregate gross offering price of common stock increased from $300M to $413.65M.","Shares offered at-the-market from time to time; prospectus supplement filed same day.","Proceeds not specified; prior ATM sales included in the increased limit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1802363286.5580997,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105305,"accession_number":"0001549595-26-000013","cik":1549595,"company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","form_type":"8-K","filed_at":"2026-01-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nurix reports FY2025 net loss of $264.5M; initiates DAYBreak registrational program for bexobrutideg","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2025 revenue $84.0M (+54% YoY); net loss $264.5M ($3.05/sh) vs $193.6M ($2.88/sh) last year.","Bexobrutideg Phase 1 in r/r CLL: 83% ORR, median PFS 22.1 months; DAYBreak pivotal Phase 2 initiated at 600 mg.","Completed $250M stock offering in Oct 2025; cash, cash equivalents & marketable securities $592.9M.","Appointed Roger Dansey to Board; Phase 3 randomized trial vs pirtobrutinib expected H1 2026.","Preclinical IRAK4 degrader GS-6791 data presented; Phase 1 HV study ongoing; autoimmune IND planned 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":83980000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1802363286.5580997,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105304,"accession_number":"0001549595-26-000003","cik":1549595,"company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nurix outlines bexobrutideg pivotal CLL plan, 83% ORR, $664M cash at JPM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 DAYBreak CLL-201 enrolled Oct 2025; confirmatory Phase 3 vs pirtobrutinib planned in 2026.","83% ORR and 22.1-month median PFS in r/r CLL with median 4 prior lines; 600 mg dose aligned with regulators.","New tablet formulation for autoimmune; IND target 2026. Partnered IRAK4 (GS-6791, Phase 1) and STAT6 (IND-enabling).","NX-1607 Phase 1a showed immune activation; confirmed partial response in MSS CRC across 82 patients.","Pro forma cash $663.8M after $250M equity raise; added CCO and two new board members."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1802363286.5580997,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121587,"accession_number":"0001549595-25-000121","cik":1549595,"company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","form_type":"8-K","filed_at":"2025-12-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Nurix releases Phase 1 CLL/SLL data: 83% ORR, 22.1mo PFS; WM ORR 75.0% at ASH 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1a CLL/SLL ORR 83.0% (47 evaluable), including 4.3% complete responses; median PFS 22.1 months, DOR 20.1 months.","Phase 1b randomized comparison: 600mg RP2D showed 83.3% ORR vs 73.7% for 200mg; PFS trend favoring 600mg.","WM (n=28 evaluable) ORR 75.0% including 10.7% VGPR; median follow-up 8.1 months, median DOR and PFS not reached.","Safety: well tolerated across doses; no dose-limiting toxicities, systemic fungal infections, or Grade 4 infections.","Pivotal Phase 2 DAYBreak-CLL-201 enrolling globally; 600mg RP2D selected for further development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1802363286.5580997,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121586,"accession_number":"0001549595-25-000117","cik":1549595,"company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Nurix appoints former Pfizer oncology chief Roger Dansey to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Dansey appointed effective Nov 6, 2025, as Class III director and member of Clinical and Commercialization Committee.","Former Chief Development Officer and Chief Oncology Officer at Pfizer; previously CMO and interim CEO of Seagen.","Initial stock option grant of 50,000 shares, vesting monthly over three years; pro rata annual retainer of $50,000.","Dansey brings experience from leading Keytruda development at Merck and Xgeva at Amgen."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1802363286.5580997,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121585,"accession_number":"0001549595-25-000115","cik":1549595,"company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","form_type":"8-K","filed_at":"2025-10-22T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Nurix initiates pivotal Phase 2 DAYBreak trial of bexobrutideg in r/r CLL with 600 mg QD dose","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["DAYBreak Phase 2 will enroll ~100 r/r CLL/SLL patients after prior cBTKi, ncBTKi, and BCL-2i; primary endpoint is ORR by IRC.","600 mg QD dose selected via Phase 1b randomized cohort; aligned with FDA, MHRA, and EMA for accelerated approval pathway.","Confirmatory Phase 3 trial planned for H1 2026 with ~400 patients comparing bexobrutideg to pirtobrutinib or chemoimmunotherapy.","NX-1607 Phase 1a data showed disease control rate 49.3% in 82 patients; confirmed partial response in MSS colorectal cancer.","Preclinical data presented claim superior degradation potency and selectivity across BTK mutations; investor webcast held Oct 22."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1802363286.5580997,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121584,"accession_number":"0001193125-25-246964","cik":1549595,"company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","form_type":"8-K","filed_at":"2025-10-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nurix raises $250M in registered offering; shares priced at $10.21","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 24,485,799 shares at $10.21/share; gross proceeds $250.0M, net ~$234.3M.","Proceeds to fund clinical development of bexobrutideg in CLL and autoimmune indications.","New and existing investors participate, including General Atlantic, Redmile, Braidwell, Deep Track, Perceptive Advisors.","Offering expected to close October 23, 2025, subject to customary conditions.","J.P. Morgan, Jefferies, Stifel act as joint book-running managers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1802363286.5580997,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121583,"accession_number":"0001549595-25-000112","cik":1549595,"company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","form_type":"8-K","filed_at":"2025-10-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nurix Q3 FY2025 net loss $86.4M ($1.03/share); cash $428.8M; bexobrutideg pivotal trials on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $7.9M vs $12.6M YoY; net loss $86.4M ($1.03/sh) vs $49.0M ($0.67/sh) YoY.","Cash and securities $428.8M (down from $609.6M at Nov 2024); R&D spend $86.1M, up 55% YoY.","Bexobrutideg ORR 80.9% in CLL (n=47) and 84.2% in WM (n=19); pivotal trials planned H2 2025.","Preclinical data for GS-6791 (IRAK4 degrader with Gilead) presented at EADV; IND-enabling STAT6 degrader with Sanofi.","Collaboration revenue declined as Sanofi initial research term ended; partially offset by Pfizer milestone completion."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":70403000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1802363286.5580997,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138241,"accession_number":"0001549595-25-000108","cik":1549595,"company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","form_type":"8-K","filed_at":"2025-09-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nurix begins investor meetings with updated clinical plans for bexobrutideg Phase 1 trial","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Company presenting updated development plans for bexobrutideg (NX-5948), an oral BTK degrader.","Phase 1 trial ongoing in patients with relapsed/refractory B cell malignancies.","Investor presentation dated September 3, 2025, furnished as Exhibit 99.1.","Specific clinical data updates not detailed in the 8-K filing text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1802363286.5580997,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138240,"accession_number":"0001549595-25-000105","cik":1549595,"company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","form_type":"8-K","filed_at":"2025-08-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Nurix director Lori Kunkel resigns; Roy Baynes named committee chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Director Lori A. Kunkel, M.D. resigns from Board and committees effective September 1, 2025.","Resignation not due to any disagreement with company on operations, policies, or practices.","Board appoints Roy D. Baynes, MB.Bch., M.Med., Ph.D., as chair of Clinical and Commercialization Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1802363286.5580997,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138239,"accession_number":"0001549595-25-000094","cik":1549595,"company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","form_type":"8-K","filed_at":"2025-07-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nurix Q2 FY2025 revenue $44.1M (+264% YoY); Sanofi extends STAT6 license; bexobrutideg 80.9% ORR in CLL","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $44.1M (vs $12.1M YoY) driven by $30M Sanofi license extensions and $5M Gilead milestone.","Net loss $43.5M ($0.52/sh) vs $44.5M ($0.71/sh) prior year; cash $485.8M.","Sanofi extended STAT6 license for $15M payment; total $127M received; up to $465M in milestones remain.","Bexobrutideg Phase 1 data: 80.9% ORR in r/r CLL including a complete response; favorable safety (no AFib, fungal infections).","FDA cleared IND for IRAK4 degrader GS-6791/NX-0479; pivotal CLL trial for bexobrutideg expects to start H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":62509000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1802363286.5580997,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155692,"accession_number":"0001549595-25-000086","cik":1549595,"company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Nurix bexobrutideg shows 80.9% ORR in CLL, 84.2% in WM; pivotal trials on track for 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ORR 80.9% in CLL/SLL (n=47 evaluable); median time to first response 1.9 months; one complete response after >2 years.","ORR 84.2% in WM (n=19 evaluable); included 10.5% VGPR, 57.9% PR; IgM reductions >90% in three patients.","Well tolerated across 50-600 mg doses; common AEs low-grade purpura/contusion (45.8%), neutropenia (29.2%); no new atrial fibrillation.","Patients heavily pretreated: median 4 prior lines, 97.9% prior BTKi, 83.3% prior BCL2i; responses seen regardless of baseline mutations or CNS involvement.","Nurix on track to initiate pivotal trials of bexobrutideg in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1802363286.5580997,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155691,"accession_number":"0001549595-25-000067","cik":1549595,"company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Nurix Therapeutics annual meeting elects directors, ratifies auditor, passes say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All three Class II director nominees elected: Reinsdorf (43.57M for), Saltzman (50.30M for), Baynes (60.82M for).","Ratification of PricewaterhouseCoopers as independent auditor for FY2025 approved (64,950,599 for, 85,040 against).","Non-binding advisory vote on named executive officer compensation passed (49,788,975 for, 11,341,365 against).","Annual meeting held May 19, 2025; 65,056,197 shares (85.33% of voting power) constituted a quorum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1802363286.5580997,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155690,"accession_number":"0001549595-25-000053","cik":1549595,"company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","form_type":"8-K","filed_at":"2025-04-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nurix posts Q1 FY2025 net loss $56.4M; bexobrutideg gets orphan drug designation","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $18.5M, up from $16.6M YoY; net loss $56.4M ($0.67/share) vs $41.5M prior year.","Cash & marketable securities $549.7M at Feb 28, 2025; down from $609.6M at Nov 30, 2024.","Earned $7M milestones in quarter; post-quarter received $15M license extension fee from Sanofi.","NX-5948 named bexobrutideg; FDA Orphan Drug for Waldenström macroglobulinemia; pivotal trials in CLL on track for 2025.","Added Roy Baynes to board and John Northcott as CCO; Sanofi exercised option to license undisclosed inflammation target."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":18453000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1802363286.5580997,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174177,"accession_number":"0001549595-25-000043","cik":1549595,"company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Nurix appoints former Merck CMO Roy Baynes to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appoints Roy D. Baynes (EVP & CMO of Eikon, former Merck CMO) as Class II director, effective March 11, 2025.","Received initial option for 50,000 shares vesting over 3 years; annual cash retainers of $50,000 (board) and $5,000 (committee).","Served on Medical Advisory Board since 2023; will advise on clinical development including NX-5948 for CLL.","No family relationships or material interests with directors/officers; standard indemnification agreement executed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1802363286.5580997,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174176,"accession_number":"0001549595-25-000014","cik":1549595,"company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","form_type":"8-K","filed_at":"2025-01-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nurix Therapeutics reports FY2024 net loss $193.6M, cash $609.6M; NX-5948 ORR 75.5%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $54.5M in FY2024, down from $77.0M YoY; net loss $193.6M ($2.88/share) vs $143.9M ($2.65) prior year.","Cash and marketable securities $609.6M as of Nov 30, 2024, up from $295.3M a year earlier.","NX-5948 achieved 75.5% objective response rate in r/r CLL/SLL; received FDA Fast Track and EMA PRIME designations.","Appointed John Northcott as Chief Commercial Officer in January 2025.","Plans to commence registration trials for NX-5948 in CLL and explore autoimmune indications in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":54549000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1802363286.5580997,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174175,"accession_number":"0001549595-25-000005","cik":1549595,"company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Nurix reports preliminary cash $609.6M; plans pivotal CLL trials for NX-5948 in 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash and investments $609.6M as of Nov 30, 2024; runway into H1 2027.","NX-5948 achieved 75.5% ORR in CLL patients; FDA Fast Track and EMA PRIME designations.","Plans to initiate pivotal studies for NX-5948 in CLL in 2025; expand into WM and inflammatory indications.","Gilead exercised option on IRAK4 degrader; Sanofi collaboration extended; STAT6 degrader candidate nomination expected H1 2025.","Strengthened leadership: promoted Dr. O'Connor as CMO and Dr. Phiasivongsa as CTO; added Anil Kapur to board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1802363286.5580997,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191122,"accession_number":"0001549595-24-000160","cik":1549595,"company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","form_type":"8-K","filed_at":"2024-12-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Nurix: NX-5948 Phase 1 CLL/SLL shows 75.5% ORR, deepens to 84.2%; safe; pivotal trials in 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ORR 75.5% (n=49) in heavily pretreated CLL/SLL; 84.2% in patients with at least 2 assessments.","Median duration of response not reached; 13 patients >6 months, 5 >1 year on treatment.","Well tolerated; only 1 grade 1 atrial fibrillation; common AEs: purpura/contusion, fatigue, petechiae, neutropenia.","Responses across baseline BTK (38.6%), PLCG2 (12.3%), TP53 (40.4%) mutations and CNS involvement (5 patients).","Company on track to initiate pivotal trials of NX-5948 in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1802363286.5580997,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191121,"accession_number":"0001193125-24-248678","cik":1549595,"company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nurix Therapeutics files $300M at-the-market stock offering via Piper Sandler","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment No.2 to Equity Distribution Agreement authorizes up to $300M aggregate gross offering price of common stock in ATM offerings.","Piper Sandler receives up to 3.0% sales commission on gross proceeds; expenses reimbursed up to $50K for this amendment.","Offering uses existing automatic shelf registration statement (File No. 333-280117) and prospectus supplement dated Oct 31, 2024.","No specific use of proceeds disclosed in the filing; proceeds will be net of commissions and expenses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1802363286.5580997,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191120,"accession_number":"0001549595-24-000138","cik":1549595,"company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","form_type":"8-K","filed_at":"2024-10-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Nurix appoints drug commercialization veteran Anil Kapur to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Anil Kapur as Class I director effective Oct 15, 2024, with term expiring at 2027 annual meeting.","Mr. Kapur brings 25+ years of pharma exec experience, including launching Imbruvica and Darzalex.","Received initial stock option for 50,000 shares vesting monthly over 3 years, plus annual equity awards.","Appointment aims to support plan to advance NX-5948 into pivotal testing in 2025 and prepare for commercialization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1802363286.5580997,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191119,"accession_number":"0001549595-24-000130","cik":1549595,"company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","form_type":"8-K","filed_at":"2024-10-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nurix Therapeutics reports Q3 FY2024 net loss $49M, $0.67 per share; cash $457.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $49.0M ($0.67 per share) vs $37.0M ($0.68 per share) in Q3 FY2023.","Collaboration revenue $12.6M, down from $18.5M, reflecting end of Gilead research term offset by Pfizer deal.","Cash and marketable securities $457.5M as of Aug 31, 2024, up from $452.5M at May 31, 2024.","NX-5948 Phase 1b expansion started in CLL, Waldenstrom's, follicular, marginal zone lymphoma; FDA Fast Track for CLL.","NX-2127 enrollment reinitiated with new chirally controlled drug product after FDA partial clinical hold lift."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":41265000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1802363286.5580997,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207591,"accession_number":"0001549595-24-000120","cik":1549595,"company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","form_type":"8-K","filed_at":"2024-09-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nurix to present updated Phase 1 NX-5948 data at investor meetings starting Sept 5","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company began investor roadshow on September 5, 2024, with an updated investor slide deck.","Deck includes new data from the Phase 1 trial of NX-5948 for various B-cell malignancies.","No specific numerical results (e.g., response rates, safety) are disclosed in this 8-K filing.","NX-5948 is a targeted protein degrader; the full presentation may contain efficacy/safety details."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1802363286.5580997,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207590,"accession_number":"0001549595-24-000097","cik":1549595,"company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","form_type":"8-K","filed_at":"2024-07-11T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Nurix posts Q2 net loss $44.5M; cash rises to $452.5M; NX-5948 ORR 69.2% in CLL","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $44.5M ($0.71/sh) vs $24.3M ($0.45/sh) YoY; collaboration revenue $12.1M (+13% YoY).","Cash and marketable securities $452.5M as of May 31, 2024, up from $254.3M after $188.7M public offering.","NX-5948 Phase 1a/b data: ORR 69.2% in heavily pretreated CLL patients; plans for pivotal trial in 2025.","Appointed Paula O'Connor as CMO and Pasit Phiasivongsa as CTO to lead clinical and CMC operations.","Entered into Amendment No.1 to equity distribution agreement allowing up to $150M ATM offerings."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":28677000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1802363286.5580997,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225038,"accession_number":"0001549595-24-000086","cik":1549595,"company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Nurix Therapeutics: NX-5948 achieves 69.2% ORR in Phase 1 CLL; pivotal trial planned for 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Objective response rate of 69.2% in 26 evaluable CLL patients across 50-600 mg daily doses; responses deepened over time.","Heavily pretreated population: median 4 prior therapies (96.8% BTKi, 90.3% BCL2i, 25.8% non-covalent BTKi).","43.3% had BTK mutations, 20% PLCG2 mutations, 46.7% TP53 mutations; CNS involvement in 2 patients responded.","NX-5948 well tolerated; common adverse events: purpura/contusion, thrombocytopenia, neutropenia.","Company plans to initiate pivotal, registration-directed trial(s) for NX-5948 in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1802363286.5580997,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225037,"accession_number":"0001549595-24-000073","cik":1549595,"company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","form_type":"8-K","filed_at":"2024-05-21T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Nurix Therapeutics annual meeting: stockholders elect directors, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders elected directors Julia P. Gregory (29.9M for, 4.5M withheld) and David L. Lacey (27.1M for, 7.3M withheld) to terms expiring 2027.","Ratified PricewaterhouseCoopers LLP as independent auditor for FY ending Nov 30, 2024 (39.0M for, 16.7K against).","Non-binding advisory vote on named executive officer compensation passed: 30.4M for, 4.0M against, 77.4K abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":1802363286.5580997,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225036,"accession_number":"0001193125-24-094875","cik":1549595,"company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","form_type":"8-K","filed_at":"2024-04-12T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Nurix prices upsized $175M public offering of 10.17M shares and prefunded warrants at $15.00/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["10,166,667 common shares at $15.00/share plus 1,500,100 pre-funded warrants at $14.999/warrant.","Gross proceeds of $175M; net proceeds estimated at ~$164M after underwriting discounts and expenses.","Proceeds to fund clinical development, R&D pipeline expansion, and working capital.","Underwriters granted 30-day option to purchase up to an additional 1.75M shares.","Offering expected to close on or about April 16, 2024, subject to customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1802363286.5580997,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225035,"accession_number":"0001549595-24-000048","cik":1549595,"company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","form_type":"8-K","filed_at":"2024-04-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nurix Therapeutics Q1 FY2024 revenue $16.6M, net loss $41.5M; Gilead collaboration extended","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $16.6M (up 31% YoY); net loss $41.5M ($0.76/sh) vs $40.7M ($0.75/sh) prior year.","Cash $254.3M vs $295.3M at Nov 30, 2023; R&D spend $50.0M (up 9% YoY).","Gilead extended collaboration by 2 years, paying $15M extension fee; total potential milestones up to $1.7B.","Sanofi extended STAT6 program; Nurix expects to nominate clinical candidate in 12 months.","FDA lifted partial clinical hold on NX-2127 (BTK degrader) in March 2024; enrollment to reinitiate."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":16585000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1802363286.5580997,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225034,"accession_number":"0001549595-24-000041","cik":1549595,"company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","form_type":"8-K","filed_at":"2024-04-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nurix announces first clinical responses in brain for BTK degrader NX-5948","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NX-5948 detected in CSF from all available samples, showing brain penetration.","CLL patient with CNS involvement achieved partial response by week 24 and cleared tumor cells from CSF.","PCNSL patient with MYC rearrangement had complete regression of three lesions at week 8, but progressed by week 16.","Data presented at AACR 2024; NX-5948 is an oral BTK degrader in Phase 1a/1b for B cell malignancies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1802363286.5580997,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244271,"accession_number":"0001549595-24-000038","cik":1549595,"company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","form_type":"8-K","filed_at":"2024-03-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA lifts partial clinical hold on Nurix's NX-2127 Phase 1 trial; enrollment to resume","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared new chirally controlled NX-2127 drug product; partial hold lifted March 11, 2024.","Enrollment reinitiated in Phase 1a/1b for relapsed/refractory B-cell malignancies.","Prioritizing aggressive NHL (DLBCL, MCL) where durable complete responses previously observed.","Patients currently enrolled and deriving benefit from prior process may continue treatment.","Company cites accelerated interest from ASH data and Science publication on BTK degrader programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1802363286.5580997,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244270,"accession_number":"0001549595-24-000024","cik":1549595,"company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","form_type":"8-K","filed_at":"2024-02-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nurix FY2023 revenue $77.0M, net loss $143.9M; NX-5948 Fast Track, NX-2127 partial hold","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2023 revenue $77.0M (up from $38.6M), net loss $143.9M ($2.65/share) vs $180.4M ($3.71) prior year.","Cash and investments $295.3M as of Nov 30, 2023, up from $268.7M at Aug 31, 2023.","NX-5948 granted FDA Fast Track for CLL; positive Phase 1 data with durable responses.","NX-2127 placed on partial clinical hold by FDA; expects to resolve in 2024.","Generated $100M non-dilutive capital from partners in 2023; licensed IRAK-4 degrader NX-0479/GS-6791 to Gilead."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1802363286.5580997,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244269,"accession_number":"0001549595-24-000003","cik":1549595,"company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nurix Therapeutics outlines 2024 priorities: BTK degrader NX-5948 acceleration, partial hold on NX-2127","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Positive Phase 1 data for NX-5948 (BTK degrader) in CLL/NHL; plans to accelerate enrollment toward pivotal trials.","NX-2127 Phase 1 partial clinical hold; Nurix expects to resolve with new drug product in ongoing trial.","Gilead licensed oral IRAK4 degrader NX-0479 for $20M fee; up to $425M milestones plus tiered royalties.","Pfizer (Seagen) collaboration for Degrader-Antibody Conjugates; $60M upfront, up to $3.4B milestones.","Cash of $329M (Aug 2023) plus $60M from Pfizer; runway into H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1802363286.5580997,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261687,"accession_number":"0001549595-23-000062","cik":1549595,"company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","form_type":"8-K","filed_at":"2023-12-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nurix reports positive Phase 1 data for BTK degraders NX-5948 and NX-2127 at ASH 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NX-5948: 3 partial responses in CLL (n=7); no DLTs or treatment-related SAEs across 50-450 mg doses.","NX-2127: 2 complete responses in NHL (MCL, DLBCL); 40.7% ORR in CLL (n=27), up from 33% at ASH 2022.","NX-2127 safety manageable: neutropenia dose-related, atrial fibrillation 11.1% (down from 17% prior).","Dose escalation continues for both programs; more data expected in 2024.","Company plans to develop NX-5948 broadly in CLL and other NHL indications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1802363286.5580997,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261686,"accession_number":"0001193125-23-275300","cik":1549595,"company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nurix presents updated clinical guidance, NX-2127 Phase 1 details","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Investor presentation includes updated guidance on clinical programs.","Additional detail on Phase 1 trial of NX-2127 for B-cell malignancies provided.","Meetings with analysts and investors begin November 13, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1802363286.5580997,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261685,"accession_number":"0001549595-23-000053","cik":1549595,"company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","form_type":"8-K","filed_at":"2023-11-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA places partial clinical hold on Nurix's NX-2127 Phase 1 trial; enrollment paused","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA partial clinical hold on U.S. Phase 1 study NX-2127-001 for B-cell malignancies; screening and enrollment paused.","Patients currently enrolled who derive clinical benefit may continue treatment per ongoing protocol.","Hold follows Nurix's communication to FDA of intention to transition to an improved manufacturing process.","Nurix's other drug programs are not affected by the NX-2127 manufacturing process improvement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1802363286.5580997,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261684,"accession_number":"0001549595-23-000046","cik":1549595,"company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","form_type":"8-K","filed_at":"2023-10-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nurix Q3 FY2023 revenue $18.5M, net loss $37.0M; Seagen collaboration yields $60M upfront","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $18.5M, up 71% YoY, driven by $8M in research milestones from Gilead and Sanofi.","Net loss of $37.0M ($0.68 per share) narrowed from $45.7M ($0.90) YoY.","Cash, equivalents and marketable securities $268.7M as of Aug 31, 2023; runway into Q2 2025.","Strategic collaboration with Seagen: $60M upfront, potential $3.4B milestones, option for U.S. profit sharing on two DAC products.","Expects initial clinical data from NX-5948, NX-2127, and NX-1607 Phase 1 trials in H2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":61828000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1802363286.5580997,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278906,"accession_number":"0001549595-23-000042","cik":1549595,"company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","form_type":"8-K","filed_at":"2023-09-07T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Nurix signs $60M upfront, $3.4B milestone deal with Seagen for DAC cancer drugs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nurix will use DELigase platform to develop protein degraders for conjugation to antibodies by Seagen.","Upfront cash payment of $60M; eligibility for up to $3.4B in research, development, regulatory and commercial milestones.","Tiered royalties: mid-single to low double digits on future sales; Nurix retains option for U.S. profit sharing and co-promotion on two products.","Seagen responsible for conjugation, preclinical/clinical development and commercialization of Degrader-Antibody Conjugates (DACs)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1802363286.5580997,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278905,"accession_number":"0001549595-23-000039","cik":1549595,"company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","form_type":"8-K","filed_at":"2023-07-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nurix Q2 net loss narrows to $24.3M ($0.45/sh) on $30.7M revenue; Gilead pays $20M for IRAK4 license","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $24.3M ($0.45 EPS) vs $45.4M ($1.01 EPS) in prior year; revenue $30.7M vs $11.4M.","Cash and marketable securities $308.6M as of May 31, 2023, down from $325.6M on Feb 28, 2023.","Gilead exercised option on NX-0479 (IRAK4 degrader) for $20M; up to $425M in milestones + royalties.","Phase 1b expansion started for NX-2127 in DLBCL and MCL; Phase 1a data for NX-5948 expected H2 2023.","NX-2127 and NX-5948 preclinical data showed potent activity against BTKi resistance mutations at AACR and ICML."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":43361000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1802363286.5580997,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297180,"accession_number":"0001549595-23-000034","cik":1549595,"company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Nurix shareholders elect all director nominees; say-on-pay passes with 58.5% support","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All three Class III directors elected: Sands (97.1%), Kunkel (87.5%), Silva (86.2%) of votes cast.","Ratification of PricewaterhouseCoopers as auditor received 99.9% of votes cast for.","Non-binding advisory say-on-pay approval: 19.9M for, 12.5M against, 1.6M abstain (58.5% support).","Notable 12.5% of votes withheld for Kunkel and 13.8% for Silva, indicating shareholder dissent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":1802363286.5580997,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297179,"accession_number":"0001549595-23-000030","cik":1549595,"company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","form_type":"8-K","filed_at":"2023-04-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nurix licenses IRAK4 degrader to Gilead for $20M; Q1 net loss $40.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Gilead exercised option to license NX-0479/GS-6791, triggering $20M payment; up to $425M in milestones plus tiered royalties up to low double-digits.","Q1 collaboration revenue $12.7M (up from $9.6M); net loss $40.7M ($0.75/share) vs $42.5M ($0.95) YoY.","Cash and marketable securities $325.6M as of Feb 28, 2023, down from $373.0M at Nov 30, 2022.","Achieved $7.5M in research milestones from Gilead ($6.5M) and Sanofi ($1.0M) during the quarter.","Anticipates presenting Phase 1 clinical data for NX-2127, NX-5948, and NX-1607 in H2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":12685000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1802363286.5580997,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297178,"accession_number":"0001193125-23-095819","cik":1549595,"company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","form_type":"8-K","filed_at":"2023-04-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Nurix Therapeutics COO Stefani A. Wolff resigns, effective May 2, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stefani A. Wolff notified resignation as COO and EVP of Product Development on April 5, 2023.","Departure effective May 2, 2023; no successor announced.","Wolff oversaw product development and operations; departure creates a senior management void."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1802363286.5580997,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317553,"accession_number":"0001193125-23-069218","cik":1549595,"company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Nurix Therapeutics discloses minimal SVB exposure; less than 1% of cash at SVB","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SVB closed by California DFPI on March 10; FDIC appointed receiver.","U.S. Treasury, Fed, FDIC: all depositors fully protected; funds accessible March 13.","Nurix's SVB account holds less than 1% of total cash, equivalents, and marketable securities.","Remaining cash held at other large, global financial institutions.","Company believes exposure is immaterial and funds will be fully available."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1802363286.5580997,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317552,"accession_number":"0001549595-23-000020","cik":1549595,"company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","form_type":"8-K","filed_at":"2023-02-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nurix reports FY2022 net loss $180.4M, cash $373M; NX-2127 shows clinical benefit in CLL","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for FY ended Nov 30, 2022: $180.4M ($3.71/shr) vs $117.2M ($2.73/shr) in FY2021; R&D expense $184.5M.","Cash and marketable securities at $373.0M on Nov 30, 2022, down from $432.9M at Nov 30, 2021; collaboration revenue $38.6M.","NX-2127 BTK degrader achieved clinical responses in heavily pretreated CLL patients with BTK inhibitor resistance mutations.","Initial PK/PD data for NX-5948 showed rapid, sustained BTK degradation; FDA clearance for US trial expansion received Dec 2022.","Nurix expects to present additional clinical data for NX-2127, NX-5948, and NX-1607 in 2H 2023; partnered 10 discovery programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1802363286.5580997,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317551,"accession_number":"0001193125-23-004115","cik":1549595,"company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nurix Therapeutics outlines 2023 clinical milestones for BTK degraders and CBL-B inhibitor at JPM Conference","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NX-2127 BTK degrader: clinical update and regulatory strategy in H2 2023.","NX-5948 BTK degrader: initial Phase 1a data and dose for expansion in H2 2023.","NX-1607 CBL-B inhibitor: Phase 1a data and dose for expansion in H2 2023.","Cash, equivalents and marketable securities of $413.6M as of Aug 2022; runway into Q4 2024.","Raised $115M in 2022; expects to select new development candidate in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1802363286.5580997,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335783,"accession_number":"0001193125-22-307328","cik":1549595,"company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","form_type":"8-K","filed_at":"2022-12-16T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Nurix amends bylaws to comply with new universal proxy rules and DGCL updates","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Revised advance notice bylaws require additional disclosures from nominating stockholders and restrict number of nominees to directors up for election.","Added compliance requirements for stockholders using universal proxy rules (Rule 14a-19), including certification and evidence submission 5 business days before meeting.","Updated meeting conduct: presiding officer may set extra attendance procedures; proxy card color must be non-white for soliciting stockholders.","Added emergency bylaw provision to allow board or committee quorum during situations preventing normal meeting requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1802363286.5580997,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335782,"accession_number":"0001193125-22-302915","cik":1549595,"company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","form_type":"8-K","filed_at":"2022-12-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nurix reports positive Phase 1 data for BTK degrader NX-2127; 33% ORR in heavily pretreated CLL","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ORR of 33% (95% CI 12-62%) in 23 CLL patients who failed median 5 prior therapies, 78% prior BTK+BCL2 inhibitors.","48% of CLL patients had BTK resistance mutations; NX-2127 showed activity regardless of mutational status.","Median follow-up 5.6 months; 14 of 23 CLL patients remained on treatment as of Sept 21, 2022 data cut.","BTK mutations resistant to covalent and non-covalent inhibitors remained susceptible to degradation by NX-2127.","Safety profile consistent with prior Phase 1a results and BTK-targeted therapies in heavily pretreated patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1802363286.5580997,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-12-13T23:59:59+00:00|335782"}